20 results on '"Casey, Nicholas"'
Search Results
2. ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.
- Author
-
Mensali, Nadia, Köksal, Hakan, Joaquina, Sandy, Wernhoff, Patrik, Casey, Nicholas P., Romecin, Paola, Panisello, Carla, Rodriguez, René, Vimeux, Lene, Juzeniene, Asta, Myhre, Marit R., Fåne, Anne, Ramírez, Carolina Castilla, Maggadottir, Solrun Melkorka, Duru, Adil Doganay, Georgoudaki, Anna-Maria, Grad, Iwona, Maturana, Andrés Daniel, Gaudernack, Gustav, and Kvalheim, Gunnar
- Subjects
CHIMERIC antigen receptors ,HEMATOPOIETIC stem cells ,OSTEOSARCOMA ,ALKALINE phosphatase ,YOUNG adults ,T cell receptors - Abstract
Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. Here we show that chimeric antigen receptor (CAR) T cells could successfully target an isoform of alkaline phosphatase, ALPL-1, which is highly and specifically expressed in primary and metastatic OS. The target recognition element of the second-generation CAR construct is based on two antibodies, previously shown to react against OS. T cells transduced with these CAR constructs mediate efficient and effective cytotoxicity against ALPL-positive cells in in vitro settings and in state-of-the-art in vivo orthotopic models of primary and metastatic OS, without unexpected toxicities against hematopoietic stem cells or healthy tissues. In summary, CAR-T cells targeting ALPL-1 show efficiency and specificity in treating OS in preclinical models, paving the path for clinical translation. Chimeric antigen receptor T (CAR-T) cells represent a breakthrough in the treatment of haematopoietic malignancies, however, in solid tumours this form of immune therapy is hampered by the scarcity of suitable targets showing high level tumour-restricted expression. Here authors generate CAR-T cells that target an osteosarcoma-specific isoform of alkaline phosphatase and show efficacy in orthotopic animal models while sparing healthy tissues. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Development of a TGFβ—IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy.
- Author
-
Beck, Carole, Casey, Nicholas Paul, Persiconi, Irene, Moharrami, Neda Nejati, Sike, Adam, Jin, Yixin, and Kyte, Jon Amund
- Subjects
CELLULAR therapy ,TRANSFORMING growth factors ,T cells ,CHIMERIC antigen receptors ,HEMATOLOGIC malignancies - Abstract
Therapy employing T cells modified with chimeric antigen receptors (CARs) is effective in hematological malignancies but not yet in solid cancers. CAR T cell activity in solid tumors is limited by immunosuppressive factors, including transforming growth factor β (TGFβ). Here, we describe the development of a switch receptor (SwR), in which the extracellular domains of the TGFβ receptor are fused to the intracellular domains from the IL-2/15 receptor. We evaluated the SwR in tandem with two variants of a CAR that we have developed against STEAP1, a protein highly expressed in prostate cancer. The SwR-CAR T cell activity was assessed against a panel of STEAP1
+/− prostate cancer cell lines with or without over-expression of TGFβ, or with added TGFβ, by use of flow cytometry cytokine and killing assays, Luminex cytokine profiling, cell counts, and flow cytometry phenotyping. The results showed that the SwR-CAR constructs improved the functionality of CAR T cells in TGFβ-rich environments, as measured by T cell proliferation and survival, cytokine response, and cytotoxicity. In assays with four repeated target-cell stimulations, the SwR-CAR T cells developed an activated effector memory phenotype with retained STEAP1-specific activity. In conclusion, the SwR confers CAR T cells with potent and durable in vitro functionality in TGFβ-rich environments. The SwR may be used as an add-on construct for CAR T cells or other forms of adoptive cell therapy. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. How CAR T Cells Breathe.
- Author
-
Forcados, Christopher, Joaquina, Sandy, Casey, Nicholas Paul, Caulier, Benjamin, and Wälchli, Sébastien
- Subjects
CHIMERIC antigen receptors ,RESPIRATION - Abstract
The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy. An important aspect of their quality concerns energy production and consumption, known as metabolism. T cells tend to adopt diverse metabolic profiles depending on their differentiation state and their stimulation level. It is therefore expected that the introduction of a synthetic molecule such as CAR, activating endogenous signaling pathways, will affect metabolism. In addition, upon patient treatment, the tumor microenvironment might influence the CAR T cell metabolism by compromising the energy resources. The access to novel technology with higher throughput and reduced cost has led to an increased interest in studying metabolism. Indeed, methods to quantify glycolysis and mitochondrial respiration have been available for decades but were rarely applied in the context of CAR T cell therapy before the release of the Seahorse XF apparatus. The present review will focus on the use of this instrument in the context of studies describing the impact of CAR on T cell metabolism and the strategies to render of CAR T cells more metabolically fit. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. TY3 YEAST RETROTRANSPOSON INTEGRASE ACTIVITY IN HUMAN CELLS: O9
- Author
-
Casey, Nicholas and Woods, Greg
- Published
- 2009
6. Removal of the Shell Coat Affects Maintenance of Epithelia in Blastocysts of the Brushtail Possum in vitro
- Author
-
Casey, Nicholas and Selwood, Lynne
- Published
- 2003
7. Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.
- Author
-
Dillard, Pierre, Casey, Nicholas, Pollmann, Sylvie, Vernhoff, Patrik, Gaudernack, Gustav, Kvalheim, Gunnar, Wälchli, Sébastien, and Inderberg, Else Marit
- Subjects
- *
RAS oncogenes , *RAS proteins , *HLA histocompatibility antigens , *ANTIGEN presenting cells , *TUMOR treatment - Abstract
T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targets for Adoptive Cell Therapy (ACT). We have isolated four KRAS-specific TCRs from a long-term surviving pancreatic cancer patient vaccinated with a mix of mutated KRAS peptides. The sequence of these TCRs could be identified and expressed in primary cells. We demonstrated stable expression of all TCRs as well as target-specific functionality when expressing T cells were co-incubated with target cells presenting KRAS peptides. In addition, these TCRs were all partially co-receptor independent since they were functional in both CD4 and CD8 T cells, thus indicating high affinity. Interestingly, we observed that certain TCRs were able to recognize several KRAS mutations in complex with their cognate Human leukocyte antigen (HLA), suggesting that, here, the point mutations were less important for the HLA binding and TCR recognition, whereas others were single-mutation restricted. Finally, we demonstrated that these peptides were indeed processed and presented, since HLA-matched antigen presenting cells exogenously loaded with KRAS proteins were recognized by TCR-transduced T cells. Taken together, our data demonstrate that KRAS mutations are immunogenic for CD4 T cells and are interesting targets for TCR-based cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy.
- Author
-
Benard, Emmanuelle, Casey, Nicholas P., Inderberg, Else Marit, and Wälchli, Sébastien
- Subjects
- *
OVARIAN cancer , *CHIMERIC antigen receptors , *T cells , *COMBINATION drug therapy - Abstract
Ovarian Cancer (OC) is currently difficult to cure, mainly due to its late detection and the advanced state of the disease at the time of diagnosis. Therefore, conventional treatments such as debulking surgery and combination chemotherapy are rarely able to control progression of the tumour, and relapses are frequent. Alternative therapies are currently being evaluated, including immunotherapy and advanced T cell‐based therapy. In the present review, we will focus on a description of those Chimeric Antigen Receptors (CARs) that have been validated in the laboratory or are being tested in the clinic. Numerous target antigens have been defined due to the identification of OC biomarkers, and many are being used as CAR targets. We provide an exhaustive list of these constructs and their current status. Despite being innovative and efficient, the OC‐specific CARs face a barrier to their clinical efficacy: the tumour microenvironment (TME). Indeed, effector cells expressing CARs have been shown to be severely inhibited, rendering the CAR T cells useless once at the tumour site. Herein, we give a thorough description of the highly immunosuppressive OC TME and present recent studies and innovations that have enabled CAR T cells to counteract this negative environment and to destroy tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Short Ladder to Nowhere: The Crisis in 'Senior Religion'
- Author
-
Casey, Nicholas A.
- Published
- 1984
10. Resource-Area-Dependence Analysis: Inferring animal resource needs from home-range and mapping data.
- Author
-
Kenward, Robert E., Arraut, Eduardo M., Robertson, Peter A., Walls, Sean S., Casey, Nicholas M., and Aebischer, Nicholas J.
- Subjects
TELEMETRY ,HOME range (Animal geography) ,SQUIRRELS ,DECIDUOUS plants ,GEOLOGICAL mapping - Abstract
An animal’s home-range can be expected to encompass the resources it requires for surviving or reproducing. Thus, animals inhabiting a heterogeneous landscape, where resource patches vary in size, shape and distribution, will naturally have home-ranges of varied sizes, so that each home-range encompasses a minimum required amount of a resource. Home-range size can be estimated from telemetry data, and often key resources, or proxies for them such as the areas of important habitat types, can be mapped. We propose a new method, Resource-Area-Dependence Analysis (RADA), which uses a sample of tracked animals and a categorical map to i) infer in which map categories important resources are accessible, ii) within which home range cores they are found, and iii) estimate the mean minimum areas of these map categories required for such resource provision. We provide three examples of applying RADA to datasets of radio-tracked animals from southern England: 15 red squirrels Sciurus vulgaris, 17 gray squirrels S. carolinensis and 114 common buzzards Buteo buteo. The analyses showed that each red squirrel required a mean (95% CL) of 0.48 ha (0.24–-0.97) of pine wood within the outermost home-range, each gray squirrel needed 0.34 ha (0.11–1.12) ha of mature deciduous woodland and 0.035–0.046 ha of wheat, also within the outermost home-range, while each buzzard required 0.54 ha (0.35–0.82) of rough ground close to the home-range center and 14 ha (11–17) of meadow within an intermediate core, with 52% of them also relying on 0.41 ha (0.29–0.59) of suburban land near the home-range center. RADA thus provides a useful tool to infer key animal resource requirements during studies of animal movement and habitat use. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. An unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia/lymphoma.
- Author
-
Casey, Nicholas, Fujiwara, Hiroshi, Azuma, Taichi, Murakami, Yuichi, Yoshimitsu, Makoto, Masamoto, Izumi, Nawa, Yuichiro, Yamanouchi, Jun, Narumi, Hiroshi, Yakushijin, Yoshihiro, Hato, Takaaki, and Yasukawa, Masaki
- Subjects
- *
T-cell lymphoma , *LYMPH nodes , *COMPUTED tomography , *INNATE lymphoid cells , *IMMUNOHISTOCHEMISTRY , *CD25 antigen - Abstract
The article presents case study of a 78-year-old Japanese woman with adult T-cell leukemia/lymphoma, who was diagnosed with CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype. It mentions information on observation of abnormal swelling of cervical, axillary, inguinal, para-aortic, and mesenteric lymph nodes, upon computed tomography scanning and gallium scintigraphy. It presents information on observation of abnormal cells positive for both CD4 and CD8 upon immunohistochemistry.
- Published
- 2018
- Full Text
- View/download PDF
12. A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy.
- Author
-
Casey, Nicholas Paul, Fujiwara, Hiroshi, Tanimoto, Kazushi, Okamoto, Sachiko, Mineno, Junichi, Kuzushima, Kiyotaka, Shiku, Hiroshi, and Yasukawa, Masaki
- Subjects
- *
LEUKEMIA treatment , *AURORA kinases , *T-cell receptor genes , *IMMUNOTHERAPY , *GENETIC transformation ,LEUKEMIA genetics - Abstract
Aurora Kinase A is a cancer-associated protein normally involved in the regulation of mitosis. Being over-expressed in a range of cancers, it is a suitable target for cell-based immunotherapy. Gene transfer of T-cell receptor sequences cognisant of HLA-A*0201-restricted Aurora Kinase A antigen has previously been shown to transfer specific immunoreactivity against the target peptide in a Human Lymphocyte Antigen-restricted manner. While T cell receptor gene-transfer has great potential in overcoming the difficulties of isolating and expanding tumour-reactive lymphocytes from a patient’s own cells, one hurdle is potential mispairing and competition between exogenous and endogenous T cell receptor chains. We have used a retroviral vector design bearing a short-interfering RNA that downregulates endogenous T cell receptor chains, without affecting expression of the transgenic T cell receptor sequences. The T cell receptor expression cassette also includes a 2A self-cleaving peptide, resulting in equimolar expression of the T cell receptor alpha and beta chains, further enhancing formation of the desired T cell receptor. Via a simple, modular cloning method, we have cloned the alpha and beta chains of the anti-Aurora Kinase A-reactive T cell receptor into this ‘siTCR’ vector. We then compared the activity of this vector against the original, ‘conventional’ vector across a panel of assays. T cell receptors expressed from the siTCR-vector retained the cytotoxic functionality of the original vector, with evidence of reduced off-target reactivity. The rate of expression of correctly-formed T cell receptors was superior using the siTCR design, and this was achieved at lower vector copy numbers. Maintaining T cell receptor efficacy with a reduced vector copy number reduces the risk of genotoxicity. The siTCR design also reduces the risk of mispairing and cross-reactivity, while increasing the functional titre. Such improvements in the safety of T cell receptor gene-transfer will be crucial for clinical applications of this technology. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Targeting Aurora Kinase with a Superior T-Cell Receptor Gene-Transfer Vector
- Author
-
Casey, Nicholas, Fujiwara, Hiroshi, Tanimoto, Kazushi, Okamoto, Sachiko, Mineno, Junichi, Kuzushima, Kiyotaka, Shiku, Hiroshi, and Yasukawa, Masaki
- Published
- 2015
- Full Text
- View/download PDF
14. Outer egg coats of the marsupial conceptus: Secretion and protein composition.
- Author
-
Casey, Nicholas P., Martinus, Ryan, and Selwood, Lynne
- Published
- 2002
- Full Text
- View/download PDF
15. Novel immunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A.
- Author
-
Casey, Nicholas Paul, Fujiwara, Hiroshi, Ochi, Toshiki, and Yasukawa, Masaki
- Subjects
- *
ADULT T-cell leukemia , *CANCER immunotherapy , *AURORA kinases , *LEUKEMIA treatment - Abstract
Adult T-cell leukemia/lymphoma is caused by infection with HTLV-1, following a long latent period. Immunotherapy targeting Aurora kinase A, a tumor-associated antigen over-expressed in adult T-cell leukemia/lymphoma, holds great therapeutic potential. We review the evidence in favor of a therapeutic strategy combining vaccination and TCR-gene transfer against this target. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
16. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.
- Author
-
Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, and Wälchli S
- Subjects
- Female, Humans, Ovarian Neoplasms drug therapy, CA-125 Antigen metabolism, Membrane Proteins
- Abstract
Background: Ovarian cancer (OC) is the leading cause of death from gynecologic malignancies in the Western world. Contributing factors include a high frequency of late-stage diagnosis, the development of chemoresistance, and the evasion of host immune responses. Currently, debulking surgery and platinum-based chemotherapy are the treatment cornerstones, although recurrence is common. As the clinical efficacy of immune checkpoint blockade is low, new immunotherapeutic strategies are needed. Chimeric antigen receptor (CAR) T cell therapy empowers patients' own T cells to fight and eradicate cancer, and has been tested against various targets in OC. A promising candidate is the MUC16 ectodomain. This ectodomain remains on the cell surface after cleavage of cancer antigen 125 (CA125), the domain distal from the membrane, which is currently used as a serum biomarker for OC. CA125 itself has not been tested as a possible CAR target. In this study, we examined the suitability of the CA125 as a target for CAR T cell therapy., Methods: We tested a series of antibodies raised against the CA125 extracellular repeat domain of MUC16 and adapted them to the CAR format. Comparisons between these candidates, and against an existing CAR targeting the MUC16 ectodomain, identified K101 as having high potency and specificity. The K101CAR was subjected to further biochemical and functional tests, including examination of the effect of soluble CA125 on its activity. Finally, we used cell lines and advanced orthotopic patient-derived xenograft (PDX) models to validate, in vivo, the efficiency of our K101CAR construct., Results: We observed a high efficacy of K101CAR T cells against cell lines and patient-derived tumors, in vitro and in vivo. We also demonstrated that K101CAR functionality was not impaired by the soluble antigen. Finally, in direct comparisons, K101CAR, which targets the CA125 extracellular repeat domains, was shown to have similar efficacy to the previously validated 4H11CAR, which targets the MUC16 ectodomain., Conclusions: Our in vitro and in vivo results, including PDX studies, demonstrate that the CA125 domain of MUC16 represents an excellent target for treating MUC16-positive malignancies., Competing Interests: Competing interests: SW, EMI, DJW, NPC and EB have filled a patent application on chimeric antigen receptor for ovarian cancer. The other authors declare no conflict of interest., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
17. In vitro re-challenge of CAR T cells.
- Author
-
Klee CH, Villatoro A, Casey NP, Inderberg EM, and Wälchli S
- Subjects
- Humans, Cell Line, Receptors, Antigen, T-Cell metabolism, T-Lymphocytes metabolism, Signal Transduction
- Abstract
Chimeric antigen receptor (CAR) T cells (CAR T) have emerged as a potential therapy for cancer patients. CAR T cells are capable of recognizing membrane proteins on cancer cells which initiates a downstream signaling in T cells that ends in cancer cell death. Continuous antigen exposure over time, activation of inhibitory signaling pathways and/or chronic inflammation can lead to CAR T cell exhaustion. In this context, the design of CARs can have a great impact on the functionality of CAR T cells, on their potency and exhaustion. Here, using CD19CAR as model, we provide a re-challenge protocol where CAR T cells are cultured weekly with malignant lymphoid cell lines BL-41 and Nalm-6 to simulate them with continuous antigen pressure over a four-week period. This protocol can be value for assessing CAR T cell functionality and for the comparison of different CAR constructs., (Copyright © 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
18. Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency.
- Author
-
Casey NP, Kyte JA, and Fujiwara H
- Subjects
- Animals, Gene Editing methods, Humans, Neoplasms genetics, Neoplasms immunology, RNA Interference, RNA, Small Interfering genetics, RNA, Small Interfering immunology, RNA, Small Interfering therapeutic use, Receptors, Antigen, T-Cell immunology, Immunotherapy, Adoptive methods, Neoplasms therapy, RNAi Therapeutics methods, Receptors, Antigen, T-Cell genetics
- Abstract
The gene transfer of T-cell receptors (TCRs) is an attractive strategy for adoptive cell therapy, allowing the transfer of reactivity against antigens that may not otherwise engender an immune response. The TCRs recognize intracellular or extracellular antigens presented in the context of MHC class I or II, respectively. This broadens the range of targets considerably, compared to antibodies and chimeric antigen receptors, that are generally confined to surface antigens. However, TCR transfer must overcome some technical hurdles, relating to interference with endogenous α- and β-TCR chains and competition with other existing TCR infrastructure of T cells. In this review, we will outline the challenges facing TCR gene transfer and compare several approaches to address them. We will then focus upon one of the most promising amongst these-RNA interference-and detail the methods involved in designing and using this technology.
- Published
- 2020
- Full Text
- View/download PDF
19. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
- Author
-
Tanaka H, Fujiwara H, Ochi F, Tanimoto K, Casey N, Okamoto S, Mineno J, Kuzushima K, Shiku H, Sugiyama T, Barrett AJ, and Yasukawa M
- Subjects
- Animals, Antibody-Dependent Cell Cytotoxicity immunology, Antineoplastic Agents, Immunological pharmacology, CD3 Complex metabolism, Cell Line, Tumor, Combined Modality Therapy, Disease Models, Animal, Female, Gene Expression, Genetic Vectors genetics, Humans, Immunotherapy, Adoptive, Killer Cells, Natural immunology, Killer Cells, Natural metabolism, Lentivirus genetics, Leukemia-Lymphoma, Adult T-Cell pathology, Leukemia-Lymphoma, Adult T-Cell therapy, Mice, Receptors, CCR4 genetics, Receptors, CCR4 metabolism, Receptors, IgG metabolism, Recombinant Fusion Proteins metabolism, T-Cell Antigen Receptor Specificity immunology, Transduction, Genetic, Xenograft Model Antitumor Assays, Antibodies, Monoclonal, Humanized pharmacology, CD3 Complex genetics, Leukemia-Lymphoma, Adult T-Cell immunology, Leukemia-Lymphoma, Adult T-Cell metabolism, Receptors, IgG genetics, Recombinant Fusion Proteins genetics, T-Lymphocytes immunology, T-Lymphocytes metabolism
- Abstract
Purpose: Mogamulizumab (Mog), a humanized anti-CC chemokine receptor 4 (CCR4) mAb that mediates antibody-dependent cellular cytotoxicity (ADCC) using FcγR IIIa (CD16)-expressing effector cells, has recently been approved for treatment of CCR4-positive adult T-cell leukemia (ATL) in Japan. However, Mog failure has sometimes been observed in patients who have accompanying chemotherapy-associated lymphocytopenia. In this study, we examined whether adoptive transfer of artificial ADCC effector cells combined with Mog would overcome this drawback., Experimental Design: We lentivirally gene-modified peripheral blood T cells from healthy volunteers and ATL patients expressing the affinity-increased chimeric CD16-CD3ζ receptor (cCD16ζ-T cells). Subsequently, we examined the ADCC effect mediated by those cCD16ζ-T cells in the presence of Mog against ATL tumor cells both in vitro and in vivo, Results: cCD16ζ-T cells derived from healthy donors killed in vitro Mog-opsonized ATL cell line cells (n = 7) and primary ATL cells (n = 4) depending on both the number of effector cells and the dose of the antibody. cCD16ζ-T cells generated from ATL patients (n = 3) also exerted cytocidal activity in vitro against Mog-opsonized autologous ATL cells. Using both intravenously disseminated model (n = 5) and subcutaneously inoculated model (n = 4), coadministration of Mog and human cCD16ζ-T cells successfully suppressed tumor growth in xenografted immunodeficient mice, and significantly prolonged their survival (P < 0.01 and P = 0.02, respectively)., Conclusions: These data strongly suggest clinical feasibility of the novel combined adoptive immunotherapy using cCD16ζ-T cells and Mog for treatment of aggressive ATL, particularly in patients who are ineligible for allogeneic hematopoietic stem cell transplantation. Clin Cancer Res; 22(17); 4405-16. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
20. Anti-PML-RARα shRNA sensitises promyelocytic leukaemia cells to all-trans retinoic acid.
- Author
-
Casey NP and Woods GM
- Abstract
The PML-RARα fusion gene disrupts the retinoic acid differentiation signal in a range of leukaemia types, promoting proliferation. We designed a shRNA to target the fusion mRNA, and the shRNA expression cassette was delivered via lentiviral transduction. Delivery of this shRNA significantly down regulated the target mRNA, with effects also evident at the protein level. When combined with ATRA administration, this down regulation of the fusion gene strongly inhibited proliferation in the NB4 PML cell line.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.